Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients
Conditions: Corneal Erosion Interventions: Drug: SHJ002; Other: Vehicle Sponsors: Sunhawk Vision Biotech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Opioid Free Versus Opioid Balanced Anesthesia in Ophthalmic Surgery
Conditions: Anesthesia and Analgesia; Anesthesia, Endotracheal Interventions: Drug: Dexmedetomidine; Drug: Fentanyl Sponsors: Indonesia University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra ® on the Ocular Surface.
Conditions: Dry Eye; Dry Eyes Chronic; Dry Eye Syndromes Interventions: Drug: PRO-190; Drug: Systane Ultra ® Sponsors: Laboratorios Sophia S.A de C.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease
Conditions: Retinal Disease Interventions: Device: Spectralis FAF imaging; Device: Optos imaging; Device: Clarus imaging Sponsors: University of Wisconsin, Madison Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive ®
Conditions: Dry Eye Disease; Dry Eye Sensation; Ocular Surface Disease Interventions: Drug: PRO-240; Drug: Optive ® Sponsors: Laboratorios Sophia S.A de C.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel ® Ofteno PF
Conditions: Dry Eye Disease; Ocular Surface Disease Interventions: Drug: PRO-229; Drug: Lagricel ® Ofteno PF Sponsors: Laboratorios Sophia S.A de C.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
Conditions: Dry Eye Disease Interventions: Drug: INV-102; Drug: Vehicle Sponsors: Invirsa, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Conditions: Orbitopathy, Graves; Thyroid Eye Disease; Ophthalmopathy Interventions: Drug: Tocilizumab Sponsors: Medical University of Warsaw Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Virtual Reality in People With Persistent Postural-Perceptual Dizziness: RCT
Conditions: Vestibular Dizziness Interventions: Other: Vestibular rehabilitation therapy; Other: Virtual reality exercises; Other: Optokinetic Stimulation exercises Sponsors: University of Jordan Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
MySpace: the Role of Vision in Representing Space
Conditions: Blindness; Visual Impairment Interventions: Device: Rehabilitation with the iReach novel multisensory medical device Sponsors: Istituto Italiano di Tecnologia Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Conditions: Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive Interventions: Drug: Mirvetuximab Soravtansine; Drug: Lubricating Eye Drops; Drug: Prednisolone acetate ophthalmic suspension 1% eye drops; Drug: Brimonidine tartrate ophthalmic solution eye drops Sponsors: ImmunoGen, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Sublingual Atropine Bioequivalence by Route of Administration (SABER)
Conditions: Atropine Bioequivalence Interventions: Drug: Atropine Sulfate Ophthalmic Solution USP, 1%; Drug: Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL) Sponsors: Biomedical Advanced Research and Development Authority; Rho Federal Systems Division, Inc.; Allucent Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract
Conditions: Age Related Cataracts Interventions: Drug: EDTA Ophthalmic Solution 2.6%; Drug: EDTA Ophthalmic Solution 1.3%; Drug: Saline Solution (Placebo) Sponsors: Livionex Inc. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI ® on the Ocular Surface of Healthy Subjects.
Conditions: Ophthalmological Agent Toxicity Interventions: Drug: PRO-231; Drug: VIGAMOXI ® Sponsors: Laboratorios Sophia S.A de C.V. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
Conditions: Dry Eye Interventions: Drug: VVN001 Ophthalmic Solution, 5%; Drug: VVN001 Ophthalmic Solution, Vehicle Sponsors: VivaVision Biotech, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
